Comparative antioxidant and hypoglycaemic effects of aqueous, ethanol and n-hexane extracts of leaf of *Vitex doniana* on streptozotocin-induced diabetes in albino rats

Yakubu, O. E. 1,2*, Ojogbane, E. 3, Nwodo, O. F. C. 2, Nwaneri-Chidozie, V. O. 4 and Dasofunjo, K. 1

1Department of Biochemistry, Faculty of Biological Sciences, University of Nigeria, Nsukka, Enugu State, Nigeria.
2Department of Medical Biochemistry, Cross River State University of Technology, Calabar, Cross River State, Nigeria.
3Department of Biochemistry, Kogi State University, Anyigba, Kogi State, Nigeria.
4Department of Biochemistry, Salem University, Lokoja, Kogi State, Nigeria.

Accepted 12 September, 2013

Several herbal preparations are used to treat diabetes, but their reported hypoglycemic effects are complex. This study therefore was designed to evaluate the effect of aqueous extract of *Vitex doniana* leaves on oxidative stress and lipid peroxidation in streptozotocin-induced diabetic and non-diabetic rats. Diabetes was induced intraperitoneally using 50 mg/kg streptozotocin, while diabetic rats were treated in 12 h cycles for four weeks with 100 mg/kg of the extract and glibenclamide (2.5 mg/kg). Nondiabetic control rats received distilled water. The levels of fasting blood sugar (FBS), thiobarbituric acid reactive substance (TBARS), aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), catalase (CAT) and superoxide dismutase (SOD) activities total, conjugated and unconjugated bilirubin concentration were assayed. The results indicate that the concentrations of TBARS, ALT, AST, ALP and bilirubin were significantly increased while the activities of SOD and CAT were reduced in the diabetic animals (p<0.05). The extract significantly increased CAT and SOD activity and reduced FBS, TBARS, ALT, AST, ALP and bilirubin concentrations significantly (p<0.05) compared to normal. However, glibenclamide treatment showed slight modification in the changes observed compared to the extract. The study concluded that the extract reversed diabetes and diabetes-induced oxidative changes in the hepatocytes, thus suggesting its use for the management of diabetic complications.

**Key words:** *Vitex doniana*, lipid peroxidation, streptozotocin-induced diabetic.

**INTRODUCTION**

Diabetes mellitus is a chronic metabolic disorder characterize by degeneration of carbohydrates, protein and fat metabolism (O’Brien and Granner, 1996). Such alterations result in increased blood glucose, which causes long-term complications in many organs. Oxidative stress in cells and tissues results from the increased generation of reactive oxygen species and/or from diseases in antioxidant defense potential (Gumieniczek et al., 2002). Lipid peroxidation of cellular structures, a consequence of free radical activity in turn...
seemed to play an important role in aging and late complications of diabetes (Ugochukwu and Cobourne, 2003; Hunkar et al., 2002) disrupting natural antioxidant defence systems and altering antioxidant enzyme activities in various tissues like the liver (Rauscher et al., 2000; Rauscher et al., 2001). On the other hand, an increase in circulating lipids may be a reason for increased lipid peroxidation in diabetes. Currently, there is a renewed and growing interest in the use of plant-based products as drugs or as ‘leads’ in the manufacture of more potent drugs (Ogbonnia et al., 2008). Several secondary plant metabolites have been shown to modify biological processes, which may reduce the risk of chronic diseases in humans (Ugochukwu et al., 2003). Globally, the prevalence of diabetes mellitus is increasing. The increase in prevalence due to the aging population structure in the developed countries and due to the globally increasing obesity, as well as stressinduced life style.

Diabetes mellitus is the sixth leading cause of death globally (Nash et al., 2001). Vitex doniana sweet, (family Verbenaceae) is a perennial shrub widely distributed in tropical West Africa, and some East African countries including Uganda, Kenya and Tanzania, and high rainfall areas. It is found in the middle belt of Nigeria particularly Kogi, Benue, and parts of the savannah regions of Kaduna, Sokoto and Kano states (Etta, 1984). It is variously called vitex (English), dinya (Hausa), dinchi (Gbanyi), uchakoro (Igbo), oriri (Yoruba) ejiji (Igala) and olih (Etsako) (Burkill, 2000). V. doniana is employed in the treatment of a variety of diseases. Hot aqueous extracts of the leaves are used in the treatment of stomach and rheumatic pains, inflammatory disorders, diarrhoea dysentery and diabetes (Irvine, 1961; Etta, 1984) indicating that the plant’s leaves may possess antidiabetic properties among others. The roots and leaves are used for nausea, colic and epilepsy (Bouquet et al., 1971; Iwu, 1993). In North-Central and eastern parts of Nigeria, the young leaves are used as vegetables or sauces and porridge for meals, especially for diabetic patients.

MATERIALS AND METHODS

Collection and preparation of plant materials

Fresh leaves of V. doniana were collected from its natural habitat in Ankpa, Kogi State, and it was identified and authenticated by the ethnobotanist in the Department of Medicinal Plant Research and Traditional Medicine of the National Institute for Pharmaceutical Research and Development (NIPRD), Abuja, Nigeria. A voucher specimen number NIPRD/H/6415 was deposited at the herbarium of the department. The plant material was dried in the laboratory at room temperature and pulverized using laboratory mortar and pestle.

Aqueous extraction

About 400 g of the pulverized sample was soaked in 2 L of distilled water (1:5 W/V) and was allowed to stand for 24 h at room temperature. The extract was filtered and the filtrate was concentrated using rotary evaporator under reduced pressure. It was allowed to dry at room temperature and stored in refrigerator prior to usage.

Ethanol / n-hexane extraction

About 400 g of the pulverized sample was soaked in 2 L (1:5 w/v) of ethanol/n-hexane (2:1 v/v) for 24 h. The extract was filtered under reduced pressure using filter paper, membrane filter and vacuum pump. Ethanol extract was separated from the n-hexane extract using separatory funnel and the filtrates were concentrated using rotary evaporator under reduced pressure respectively. The extracts were reconstituted freshly in distilled water at appropriate concentrations for the various experimental doses using the equation of Tedong et al. (2007):

\[ V(ml) = \frac{(D \times P)}{C} \]

Where D = dose used (g/kg body weight); P = body weight (g); C = concentration (g/ml) and V = volume.

Animal management

Male albino rats (7 to 8 weeks old) were purchased from the animal house of the Department of Biosciences, Salem University, Lokoja, Nigeria. They were acclimatized for two weeks prior to commencement of experiment. They were kept at room temperature and maintained ad libitum on growers mash (feed) and weighed prior to experiment.

Induction of diabetes

Rats were fasted overnight and experimental diabetes was induced by intraperitoneal injection of streptozotocin (STZ) with a single dose of 50 mg/kg body weight. STZ was dissolved in a freshly prepared 0.1 M cold citrate buffer of pH 4.5 (Rakieten et al., 1963). Control rats were similarly injected with citrate buffer. Because STZ is capable of inducing fatal hypoglycemia as a result of massive pancreatic insulin release, STZ treated rats were provided with 10% glucose solution after 6 h for the next 24 h to prevent severe hypoglycemia. After 3 days for development and aggravation of diabetes, rats with moderate diabetes (that is, blood glucose concentration 250 mg/dl) that exhibited hyperglycemia were selected for experiment (Canepa et al., 1990).

Experimental design

In the experiment, the rats were divided into nine groups of five rats each and treatment was carried out orally. Group 1: (N. control) normal rats (non-diabetic, no treatment); Group 2: (D. control) diabetic rats, no treatment; Group 3: (D. STD) diabetic rats treated with 2.5 mg/kg glibenclamide; Group 4: (D. aqueous) diabetic rats treated with 100 mg/kg aqueous extract; Group 5: (D. ethanol) diabetic rats treated with 100 mg/kg of the ethanol extract; Group 6: (D. hexane) diabetic rats treated with 100 mg/kg of the n-hexane extract; Group 7: (N. aqueous) non-diabetic rats treated with 100 mg/kg aqueous extract; Group 8: (N. ethanol) non-diabetic rats treated with 100 mg/kg of ethanol extract; Group 9: (N. hexane) non-diabetic rats treated with 100 mg/kg of n-hexane extract.

On the 28th day of post-treatment, the animals were fasted overnight, anesthetized with chloroform and sacrificed by humane
decapitation. Blood was collected in centrifuge tubes, and serum collected after centrifugation at 2,000 rpm for 10 min and stored in deep-freezer prior to analysis. Fasting blood glucose and packed cell volume was monitored weekly. Liver and kidneys were surgically removed, immediately washed with ice-cold normal saline and used for the assay of TBARS and antioxidant enzymes.

**Tissue preparation**

Weighed liver and kidney samples were homogenised separately in 10 parts (w/v) of ice-cold 50 mM Tris-HCl, (pH 7.4) using a homogeniser (Janke and Kunkel, Germany). The homogenates were centrifuged at 3,000 rpm for 15 min and the supernatants were collected. The supernatants were used for measurement of scavenging enzyme activities and lipid peroxides (TBARS).

**Determination of fasting blood sugar**

Fasting blood sugar (FBS) was determined using Accu-Check Advantage glucometer.

**Determination of biochemical parameters**

**Thiobarbituric acid reactive substances (TBARS)**

Hepatic lipid peroxidation was determined as thiobarbituric acid reactive substances as described by Torres et al. (2004). Lipid peroxidation generates peroxide intermediates which upon cleavage release malondialdehyde, a product which react with thiobarbituric acid. The product of the reaction is a coloured complex which absorbs light at 535 nm. The extinction coefficient, 1.56 × 10^5 M^−1 cm^−1 was used in the calculation of TBARS and values were expressed as nmol/mg protein.

**Aspartate aminotransferase (AST)**

Aspartate aminotransferase (AST) catalyzes the transamination of aspartate to alpha-ketoglutarate to form glutamate and oxaloacetate, which then reacts with 2,4-dinitro-phenylhydrazine to form hydrazone derivative of oxaloacetate, a coloured complex which can be measured at 546 nm. Aspartate aminotransferase was determined as described by Reitman and Frankel (1957) using assay kits (Agape Laboratories Ltd, UK).

**Alanine aminotransferase (ALT)**

Alanine aminotransferase (ALT) catalyzes the transamination of alanine to alpha-ketoglutarate to form glutamate and pyruvic acid, which then reacts with 2,4-dinitro-phenylhydrazine to form hydrazone derivative of pyruvate, a coloured complex which can be measured at 546 nm. Alanine aminotransferase was determined as described by Reitman and Frankel (1957) using assay kits (Agape Laboratories Ltd, UK).

**Alkaline phosphatase (ALP)**

Serum alkaline phosphatase was determined as described by Klein et al. (1960). Serum alkaline phosphatase catalyses the hydrolysis of a colourless substrate of phenolphthalein monophosphate giving rise to phosphoric acid and phenolphthalein which, at alkaline pH values turns into a pink colour that can be determined photometrically at 550 nm.

**Serum bilirubin**

This was determined colorimetrically according to the method described by Jendrassick and Grof (1938) using assay kits (Agape Laboratories Ltd, UK). Conjugated bilirubin reacts with diazotized sulphanilic acid in alkaline medium to form a blue complex. Total bilirubin is determined in the presence of caffeine, which releases albumin bound bilirubin, by the reaction with diazotized sulphanilic acid.

**Assay of enzymatic antioxidant**

**Superoxide dismutase (SOD)**

The activity of superoxide dismutase was measured at 560 nm according to the method described by Martin et al. (1987). Briefly, auto-oxidation of hematoxylin is inhibited by SOD at assay pH, the percentage of inhibition is linearly proportional to the amount of SOD present within a specific range, and was expressed as unit/mg protein.

**Catalase (CAT)**

Catalase activity was measured using the method of Abei (1974). The decomposition rate of H₂O₂ was measured at 240 nm for 5 min using a spectrophotometer. A molar extinction coefficient of 0.041 mM^−1 cm^−1 was used to calculate the catalase activity and was expressed in unit/mg protein.

**Statistical aAnalysis**

All the values estimations were expressed as mean ± standard deviation and analyzed for ANOVA and post hoc Duncan’s -test using SPSS. Differences between groups were considered significant at P <0.05 levels.

**RESULTS AND DISCUSSION**

**Thiobarbituric acid reactive substances (TBARS) levels**

TBARS level was significantly (p<0.05) elevated in the liver of diabetic control rats, when compared with the normal control rats. This increase was reduced significantly (p<0.05) in the extract treated rats as well as in the rats treated with glibenclamide (Table 1).

**Effects of the extract on hepatic enzymes**

Hepatic enzymes; alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase (ALP) are shown in Table 2. Glibenclamide caused significant elevation (P<0.05) in the activities of these enzymes in the serum. Treatment with V. doniana aqueous extract at the dose of 100 mg/kg significantly reduced the activity of the enzymes compared to the control. Similarly, treatment with glibenclamide was able to reduce ALP activity significantly but non-significant in
Table 1. TBARS levels in normal and diabetic rats treated with V. doniana aqueous, ethanol and n-hexane extract and glibenclamide.

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Serum TBARS</th>
<th>Liver TBARS</th>
<th>Kidney TBARS</th>
</tr>
</thead>
<tbody>
<tr>
<td>N. control</td>
<td>0.41±0.02</td>
<td>0.62±0.08</td>
<td>0.56±0.13</td>
</tr>
<tr>
<td>D. control</td>
<td>0.94±0.26</td>
<td>1.86±0.23</td>
<td>1.23±0.11</td>
</tr>
<tr>
<td>D. STD</td>
<td>0.44±0.10</td>
<td>0.62±0.08</td>
<td>0.52±0.10</td>
</tr>
<tr>
<td>D. AQ (100 mg)</td>
<td>0.40±0.05</td>
<td>0.62±0.12</td>
<td>0.57±0.02</td>
</tr>
<tr>
<td>D. ETH (100 mg)</td>
<td>0.32±0.07</td>
<td>0.57±0.03</td>
<td>0.54±0.08</td>
</tr>
<tr>
<td>D. HEX (100 mg)</td>
<td>0.60±0.07</td>
<td>0.61±0.03</td>
<td>0.56±0.03</td>
</tr>
<tr>
<td>N. AQ (100 mg)</td>
<td>0.36±0.01</td>
<td>0.46±0.02</td>
<td>0.44±0.01</td>
</tr>
<tr>
<td>N. ETH (100 mg)</td>
<td>0.42±0.04</td>
<td>0.45±0.05</td>
<td>0.44±0.09</td>
</tr>
<tr>
<td>N. HEX (100 mg)</td>
<td>0.44±0.09</td>
<td>0.48±0.02</td>
<td>0.53±0.10</td>
</tr>
</tbody>
</table>

N. control = Normal control; D. control = diabetic control; D. STD = diabetic standard drug (glibenclamide); D. AQ = diabetic aqueous extract; D. ETH = diabetic ethanol extract; D. HEX = diabetic hexane extract; N. AQ = non diabetic aqueous extract; N. ETH = non diabetic ethanol extract; N. HEX = non diabetic hexane extract.

Table 2. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) activity in normal and diabetic rats treated with V. doniana aqueous, ethanol and n-hexane extract and glibenclamide.

<table>
<thead>
<tr>
<th>Treatment</th>
<th>ALT</th>
<th>AST</th>
<th>ALP</th>
</tr>
</thead>
<tbody>
<tr>
<td>N. control</td>
<td>35.71±05.63</td>
<td>34.39±10.58</td>
<td>32.81±4.00</td>
</tr>
<tr>
<td>D. control</td>
<td>55.10±04.58</td>
<td>44.59±8.74</td>
<td>79.20±9.09</td>
</tr>
<tr>
<td>D. STD</td>
<td>42.43±07.70</td>
<td>35.96±8.80</td>
<td>39.67±8.53</td>
</tr>
<tr>
<td>D. AQ (100 mg)</td>
<td>36.66±05.84</td>
<td>34.47±7.46</td>
<td>35.96±8.80</td>
</tr>
<tr>
<td>D. ETH (100 mg)</td>
<td>35.71±05.78</td>
<td>38.66±12.16</td>
<td>30.06±8.85</td>
</tr>
<tr>
<td>D. HEX (100 mg)</td>
<td>36.53±05.36</td>
<td>48.32±11.64</td>
<td>36.74±4.73</td>
</tr>
<tr>
<td>N. AQ (100 mg)</td>
<td>31.82±03.77</td>
<td>37.48±11.18</td>
<td>29.12±7.79</td>
</tr>
<tr>
<td>N. ETH (100 mg)</td>
<td>33.94±03.77</td>
<td>47.26±10.56</td>
<td>29.12±7.79</td>
</tr>
<tr>
<td>N. HEX (100 mg)</td>
<td>34.29±02.66</td>
<td>42.90±7.60</td>
<td>28.62±3.01</td>
</tr>
</tbody>
</table>

N. control = normal control; D. control = diabetic control; D. STD = diabetic standard drug (glibenclamide); D. AQ = diabetic aqueous extract; D. ETH = diabetic ethanol extract; D. HEX = diabetic hexane extract; N. AQ = non diabetic aqueous extract; N. ETH = non diabetic ethanol extract; N. HEX = non diabetic hexane extract.

ALT and AST. However, treatment of non-diabetic rats caused no significant decrease in the activity of the enzymes compared with the normal rats.

**Fasting blood sugar (FBS)**

Table 3 shows the levels of fasting blood sugar (FBS) in the animals. At day one (before induction), there was no statistical difference in the levels of FBS across the groups. At week two, there was significant (P<0.05) elevation of FBS in the diabetic groups compared to the normal groups. Treatment of diabetic animals with the extracts was able to restore FBS to normalcy across the week, with aqueous and ethanol extracts more effective than n-hexane and glibenclamide.

**Effects of the extract on enzymatic antioxidants**

A significant (p<0.05) decrease in catalase (CAT) and superoxide dismutase (SOD) activities were observed in the diabetic untreated rats compared to the normal rats (Tables 4 and 5). Treatment with the extract and glibenclamide showed a significant (p<0.05) increase in catalase activity, and glibenclamide treatment also significantly increased SOD activity but was non-significant with extract treatment compared to the normal group. There was no significant increase in the activity of the enzymes in non-diabetic rats treated with the extract compared to the normal.

**Effects of the extract on serum bilirubin**

Administration of streptozotocin caused significant (P<0.05)
The extract produced significant elevation in serum total, direct and indirect bilirubin concentration in the control animals compared to normal (Table 6). Both extract and glibenclamide treatment caused significant reduction in bilirubin concentration in the experimental rats compared to normal. However, administration of extract to normal rat showed no significant increase/decrease in total, direct and indirect bilirubin concentration.

**DISCUSSION**

Diabetes is currently considered as a vascular disease (Ibrahim and Rizk, 2008). It has also been considered by researchers that hyperglycaemia-induced oxidative stress is a critical pathogenic mechanism that initiates a plethora of cascade metabolic and vascular perturbations (Ibrahim and Rizk, 2008; Housom et al., 2001; Hunt et al., 1988). Studies have revealed the beneficial effects of some secondary plant metabolites that possess antioxidant activity in diabetes management. Lipid peroxidation was investigated in our study by assessing the hepatic levels of TBARS; a significant increase in TBARS levels of diabetic rats was observed when compared to normal control rats. Numerous studies with human and animal models have also shown increased lipid peroxidative status in membranes of different tissues in diabetes (Feillet-Coudray et al., 1999; Kakkar et al., 1998; Aydin et al., 2001; Obresova et al., 2003, Ugochukwu and Courbone, 2003). The extract produced significant decreases in TBARS levels in treated diabetic rats when compared to diabetic control rats. Treatment with glibenclamide also caused a slight decrease in TBARS levels of the treated rats. These reductions could lead to a decrease in oxidative stress and hence a reduction in the rate of progression of diabetic complications in the liver. Table 2 represents the changes in the activities of aspartate transaminase, alanine transaminase and alkaline phosphatase.

In the assessment of liver damage by the determination
of enzyme, enzyme levels such as aspartate transaminase and alanine transaminase are largely used. Elevated levels of serum enzymes are indicative of cellular leakage and loss of functional integrity of cell membrane in liver (Watkins and Seef, 2006). Hepatocellular necrosis leads to high level of serum markers in the blood, among these, aspartate transaminase, alanine transaminase are largely used.

Table 5. Superoxide dismutase (SOD) activity in normal and diabetic rats treated with V. doniana aqueous, ethanol and n-hexane extract and glibenclamide.

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Serum SOD</th>
<th>Liver SOD</th>
<th>Kidney SOD</th>
</tr>
</thead>
<tbody>
<tr>
<td>N. control</td>
<td>70.17±9.05</td>
<td>51.16±6.33</td>
<td>32.16±9.08</td>
</tr>
<tr>
<td>D. control</td>
<td>40.20±5.16</td>
<td>25.58±5.16</td>
<td>25.45±5.12</td>
</tr>
<tr>
<td>D. STD</td>
<td>53.60±9.10</td>
<td>48.98±5.49</td>
<td>34.11±7.16</td>
</tr>
<tr>
<td>D. AQ (100 mg)</td>
<td>45.60±8.00</td>
<td>34.23±3.10</td>
<td>46.84±3.75</td>
</tr>
<tr>
<td>D. ETH (100 mg)</td>
<td>53.61±4.30</td>
<td>50.45±6.44</td>
<td>47.22±5.43</td>
</tr>
<tr>
<td>D. HEX (100 mg)</td>
<td>45.21±1.54</td>
<td>34.11±8.16</td>
<td>42.24±1.44</td>
</tr>
<tr>
<td>N. AQ (100 mg)</td>
<td>62.64±4.69</td>
<td>51.00±5.00</td>
<td>33.03±3.11</td>
</tr>
<tr>
<td>N. ETH (100 mg)</td>
<td>78.04±11.63</td>
<td>56.27±2.15</td>
<td>44.49±4.87</td>
</tr>
<tr>
<td>N. HEX (100 mg)</td>
<td>82.67±5.44</td>
<td>60.73±5.21</td>
<td>34.46±3.43</td>
</tr>
</tbody>
</table>

N. control = Normal control; D. control = diabetic control; D. STD = diabetic standard drug (glibenclamide); D. AQ = diabetic aqueous extract; D. ETH = diabetic ethanol extract; D. HEX = diabetic hexane extract; N. AQ = non diabetic aqueous extract; N. ETH = non diabetic ethanol extract; N. HEX = non diabetic hexane extract. Values are mean ± SD, n = 5. All treated groups are compared with control. Values with different superscript across the group are statistically significant at P<0.05.

Table 6. Serum total bilirubin concentration in normal and diabetic rats treated with V. doniana ethanol extract and glibenclamide.

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Total bil</th>
<th>Indirect bil</th>
<th>Direct bil</th>
</tr>
</thead>
<tbody>
<tr>
<td>N. control</td>
<td>0.68±0.14</td>
<td>0.34±0.07</td>
<td>0.40±0.07</td>
</tr>
<tr>
<td>D. control</td>
<td>1.66±0.14</td>
<td>0.89±0.10</td>
<td>0.77±0.04</td>
</tr>
<tr>
<td>D. STD</td>
<td>0.88±0.24</td>
<td>0.36±0.03</td>
<td>0.52±0.04</td>
</tr>
<tr>
<td>D. AQ 100 mg</td>
<td>0.84±0.20</td>
<td>0.54±0.01</td>
<td>0.39±0.06</td>
</tr>
<tr>
<td>D.ETH 100 mg</td>
<td>0.67±0.17</td>
<td>0.37±0.07</td>
<td>0.39±0.04</td>
</tr>
<tr>
<td>D. HEX 100 mg</td>
<td>0.85±0.13</td>
<td>0.39±0.09</td>
<td>0.46±0.04</td>
</tr>
<tr>
<td>N. AQ 100 mg</td>
<td>0.58±0.08</td>
<td>0.28±0.00</td>
<td>0.39±0.03</td>
</tr>
<tr>
<td>N. ETH 100 mg</td>
<td>0.51±0.01</td>
<td>0.27±0.01</td>
<td>0.34±0.08</td>
</tr>
<tr>
<td>N. HEX 100 mg</td>
<td>0.63±0.18</td>
<td>0.31±0.04</td>
<td>0.37±0.08</td>
</tr>
</tbody>
</table>

N. control = Normal control; D. control = diabetic control; D. STD = diabetic standard drug (glibenclamide); D. AQ = diabetic aqueous extract; D. ETH = diabetic ethanol extract; D. HEX = diabetic hexane extract; N. AQ = non diabetic aqueous extract; N. ETH = non diabetic ethanol extract; N. HEX = non diabetic hexane extract. Values are mean ± SD, n = 5. All treated groups are compared with control. Values with different superscript across the group are statistically significant at P<0.05.

of enzyme, enzyme levels such as aspartate transaminase and alanine transaminase are usually increased in response to cholestasis and increased biliary pressure (Handa and Sharma, 1990). Increased level was obtained owing to streptozotocin administration and it was brought to normal level by the extract treatment. Treatment with V. doniana aqueous leaf extract decreased the serum levels of aspartate transaminase, alanine transaminase and alkaline phosphatase towards the respective normal value; that is an indication of stabilization of plasma membrane as well as repair of hepatic tissue damage caused by STZ. The aforementioned changes can be considered as an expression of the functional improvement of hepatocytes, which may be caused by an accelerated regeneration of parenchymal cells.

Hyperbilirubinemia was observed due to excessive heme
destruction and blockage of biliary tract. As a result of blockage of the biliary tract, there was mass inhibition of the conjugation reaction and release of unconjugated bilirubin from damaged and dead hepatocytes; this is in line with the report given by Gaw et al. (1999). Administration of extract decreased the level of bilirubin, suggesting that it offered protection. Catalase which has been known to scavenge and detoxify $H_2O_2$ showed a decreased activity in the diabetic control rats probably due to decreased concentration by $H_2O_2$ in the system (Esra et al., 2004).

Treatment with the extract significantly (p>0.05) increased the activity in the treated rats indicating a possible attenuation of oxidant stress. SOD activity was observed to decrease in the diabetic rats compared to the normal control rats probably acting in a compensatory mechanism to maintain homeostasis. The increase in SOD activity may also be due to decreased mutation of superoxide anions due to their decreased production at the onset of diabetes. The diabetic rats treated with the extract showed increased SOD activity while treatment with glibenclamide demonstrated less increase in SOD activity. This suggests that the extract may have reduced the production of ROS with a concomitant increase in SOD activity.

Our observations are in well agreement with the reports by several workers that STZ-induced diabetes mellitus and insulin deficiency leads to increased blood glucose (Chaudre et al., 2001). It has been reported that STZ at lower doses (50 mg/ kg) produce partial destruction of pancreatic β-cells with permanent diabetes condition (Aybar et al., 2002) and there may be more possibility of many surviving β-cells (Cherian et al., 1992). Since a much low dose of STZ was chosen for this study, there may be many surviving β-cells, capable of undergoing regeneration. Prolonged administration of extract may stimulate the β-cells of islets of Langerhans to produce insulin (Cherian et al., 1992).

The antihyperglycemic effect of the extracts was compared with glibenclamide, a standard hypoglycemic drug. Glibenclamide has long been used to treat diabetes, to stimulate insulin secretion from the pancreatic β-cells. From the results, it appears that still insulin producing β-cells are functioning in STZ treated diabetic rats and stimulation of insulin release could be responsible for most of the observed metabolic activities. Further, the observed blood glucose-lowering effect in fasted normal and STZ induced diabetic rats could possibly be due to the increased peripheral glucose utilization. A number of other plants have also been shown to exert hypoglycemic activity through stimulation of insulin release (Pari and Maheswari, 2000; Prince and Menon, 2000).

Our results therefore indicate that the aqueous extract when used for diabetes management may control and or prevent the development of diabetic complications arising from increased oxidative stress and lipid peroxidation.

REFERENCES


